FDA Inspection
GSK LLC (GlaxoSmithKline)GSK LLC (GlaxoSmithKline) – FDA Inspection, Nov 1, 2012
Record Details
This FDA Inspection record concerns GSK LLC (GlaxoSmithKline), with an inspection on November 1, 2012, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- GSK LLC (GlaxoSmithKline)
- Inspection Date
- November 1, 2012
- Product Type
- Drugs
View Company Profile
ID · 6a59303c-a690-4300-8bae-39abb1bffe78
Inspection Facts
No Action Indicated (NAI)
No objectionable conditions or practices were found during the inspection.
- Inspection number
- 805603
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
Other FDA inspections of GSK LLC (GlaxoSmithKline)
8| Date | Classification | Office | Project area |
|---|---|---|---|
| August 19, 2026 | Not classified | Philadelphia District Office | |
| October 21, 2025 | Not classified | Philadelphia District Office | |
| November 22, 2024 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| October 24, 2022 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| August 12, 2022 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for GSK LLC (GlaxoSmithKline)
- FDA Inspection 1318026 - 2026-08-19
- FDA Inspection 1269601 - 2025-10-21
- FDA Inspection 1253764 - 2024-11-22
- FDA Inspection 1187325 - 2022-10-24
- FDA Inspection 1180594 - 2022-08-12
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.